Back on Track: A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient Outcomes Among Patients With Back Pain

Sponsor
Kaiser Permanente (Other)
Overall Status
Completed
CT.gov ID
NCT03393143
Collaborator
Patient-Centered Outcomes Research Institute (Other), OCHIN, Inc. (Other), Harvard Pilgrim Health Care (Other)
2,748
1
28
98.1

Study Details

Study Description

Brief Summary

Back on Track is a quasi-experimental, mixed-methods study of a unique natural experiment that will answer the question: what is the comparative effectiveness of different payer or health-system strategies that aim to prevent unsafe opioid prescribing? The State of Oregon is enacting a Medicaid reimbursement policy to enhance access to evidence-based non-pharmacotherapeutic treatment options while restricting reimbursement for opioids for back pain. We will assess whether the policy decreases unsafe opioid prescribing and improves patient outcomes compared with usual back pain treatment practices in a comparable state, California, that is not changing Medicaid payment policy.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Back pain is one of the most common reasons patients seek medical care, and it can have a big impact on patients' quality of life and functioning. Patients and providers are becoming more frustrated with common back pain treatments like the long-term use of opioid medications and steroid injections, which have been shown to have limited long-term impact on patients' pain and day-to-day functioning and can have safety risks.

    The State of Oregon recently changed what back and neck pain treatments they cover for its Medicaid enrollees. This started to affect those insured by Medicaid in July 2016 and was implemented by January 2018. These changes ended payments for treatments like long-term opioid therapy and injections. They also expanded coverage for nondrug treatments, such as acupuncture, osteopathic or chiropractic manipulation, physical/occupational therapy, and cognitive behavioral therapy. While experts agree that opioid use must be reduced, Oregon is among the first states to try such strong measures to promote nondrug treatments and prevent the use of long-term opioid treatment for back and neck pain.

    The Oregon Medicaid reimbursement changes for back and neck pain treatment create the opportunity for a "natural experiment." In this mixed-methods, observational study, we will evaluate the impact of the reimbursement changes by comparing outcomes among patients with back pain in Oregon who will have access to these expanded nondrug treatments to similar patients seen in comparable clinics in California where expanded services for back and neck pain are not covered by the type of comprehensive payer incentive undertaken in Oregon.

    Specifically, we will use electronic health record, Medicaid claims data, and data obtained from a longitudinal patient survey to assess the impact of the changes on:

    • Patients' pain severity, pain related functioning, and satisfaction with care

    • Patients' use of pain-related health care services

    • Opioid use

    • Unintended consequences, such as the use of illicit drugs (While we expect the Oregon Medicaid change to result in many positive changes, limiting the use of opioids and pain reducing procedures like injections may motivate some individuals to use drugs that were not prescribed by their doctor.)

    In addition, we will use qualitative research methods to characterize the facilitators and barriers experienced by patients, health care providers, and clinic administrators and staff in adopting the Medicaid reimbursement changes and their satisfaction with the constellation of available and utilized services.

    Thus, this study has three components: 1) patient survey, 2) administrative data-based study (data-only), and 3) qualitative evaluation. This record focuses on the component of the study in which subjects are able to enroll - the patient survey.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    2748 participants
    Observational Model:
    Cohort
    Time Perspective:
    Other
    Official Title:
    PCORI-1609-36568 A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient Outcomes Among Patients With Back Pain
    Actual Study Start Date :
    May 31, 2018
    Actual Primary Completion Date :
    Sep 30, 2020
    Actual Study Completion Date :
    Sep 30, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Oregon patients

    Adult Medicaid patients with back pain who get their care in community health clinics in Oregon

    California patients

    Adult Medicaid patients with back pain who get their care in community health clinics in California

    Outcome Measures

    Primary Outcome Measures

    1. Pain severity [Baseline to 12 months]

      Modified 10-item version of the Brief Pain Inventory-Short Form (BPI-SF), composite of pain intensity (3 items) and pain-related interference (7 items) subscales (10 items total; continuous)

    2. Use of pain-related services [Baseline to 12 months]

      Use of pain-related services will be assessed by asking about use (Yes/no; binary) of the following pain-related services: Acupuncture, Chiropractic, Massage Therapy, Rehabilitation Therapies; Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT); Psychotherapy, Yoga Group or Class, and Stretching/Strengthening Exercise Therapy.

    3. Patient satisfaction with health care services [Baseline to 12 months]

      Patient satisfaction with health care services will be assessed by asking the following question: How satisfied have you been with the services you've received to help you manage your pain? (0-10 scale; continuous; higher score = more satisfied)

    4. Negative outcomes related to pain services [Baseline to 12 months]

      Negative outcomes related to pain services will be assessed by asking the following question: Have you had any problems or bad outcomes from services that you have received or things you've done to manage your pain? (Yes/no; binary) If respond yes, a description of the problem or bad outcome is collected.

    5. Illicit drug use [Baseline to 12 months]

      Illicit drug use will be assessed by asking the following four questions: Have you used an opioid prescription medication that was not prescribed for you by your health care provider? (Yes/no; binary) Have you used any street drugs to manage your pain? (Yes/no; binary) If respond yes, a description of the street drug(s) is collected. Have you used any other types of prescription medications that were not prescribed for you by a health care provider to manage your pain? (Yes/no; binary) If respond yes, a description of the prescription medication(s) is collected. Have you used heroin to manage your pain? (Yes/no; binary)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion criteria:
    1. Adults age 18-65 years

    2. Insured by Medicaid

    3. Have back or neck pain (based on ICD-CM diagnosis)

    4. Receive their primary health care at participating OCHIN member federally qualified health centers in Oregon and California

    Exclusion criteria:
    1. Patients with current malignant cancer diagnosis

    2. Any evidence of patient having received hospice or other end-of-life palliative care within the past year

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 OCHIN, Inc. Portland Oregon United States 97201

    Sponsors and Collaborators

    • Kaiser Permanente
    • Patient-Centered Outcomes Research Institute
    • OCHIN, Inc.
    • Harvard Pilgrim Health Care

    Investigators

    • Principal Investigator: Lynn DeBar, PhD, MPH, Kaiser Permanente

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kaiser Permanente
    ClinicalTrials.gov Identifier:
    NCT03393143
    Other Study ID Numbers:
    • R217083
    First Posted:
    Jan 8, 2018
    Last Update Posted:
    Jan 11, 2021
    Last Verified:
    Jan 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Kaiser Permanente
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 11, 2021